AzTrials
AzTrials

Pre-eclampsiaTREMOFLONCT07695909

Gestational Changes in Hemodynamics and Respiratory Mechanics in Association With Pre-Eclampsia

An observational study of Pre-eclampsia and Pregnancy, run by Icahn School of Medicine at Mount Sinai at 1 site in United States.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record

Search all trials

Trial summary

This study focuses on elucidating the changes of hemodynamics assessed by USCOM and respiratory mechanics assessed by impedance oscillometry (IOS) over the course of pregnancy and the postpartum period. Additionally, to understand how these changes over the course of gestation relate to the development of preeclampsia. Read more about this study

Who is it for?
Ages 18 to 50 years, women only
Conditions the study is for
Pre-eclampsia, Pregnancy, Post Partum
How many people
100 participants
Where
1 siteUnited States
Study dates
Oct 2026to Aug 2028
Phase
Observational

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 50 years
  • Women only
  • No healthy volunteers
  • Adult

Study population: Patients attending prenatal visits at Mount Sinai will be screened for eligibility by study staff.

Who may be able to join

  • Pregnant patient
  • Aged 18-50 years old
  • Planning to deliver in Mount Sinai Health System

Who cannot join

  • Multiple gestation (i.e., twins)
  • Known fetal anomalies or genetic abnormalities

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Nicola F Tavella, MPH contact

212-241-3888

nicola.tavella@mssm.edu

United States1 site
  • Icahn School of Medicine at Mount Sinai

    New York, New York, 10029

    Nicola F Tavella, MPH, 212-241-3888, nicola.tavella@mssm.edu

    Angela Bianco, MD

Other trials in United States

About this study

Official title: TREMOFLO: Gestational Changes in Hemodynamics and Respiratory Mechanics in Association With Pre-eclampsia

This study focuses on elucidating the changes of hemodynamics assessed by USCOM and respiratory mechanics assessed by impedance oscillometry (IOS) over the course of pregnancy and the postpartum period. Additionally, to understand how these changes over the course of gestation relate to the development of preeclampsia.

Medical subject headings
Pre-Eclampsia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07695909
Study groupRoleWhat they receive
Observational GroupDuring pregnancy and the post-partum period, participants enrolled in this study will have observational hemodynamic and oscillometer measurements taken which will be analyzed alongside individuals' pregnancy outcomes as they relate to hypertensive disorders of pregnancy and, specifically, pre-eclampsia.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Stroke Volume

    The volume of blood pumped out of the left ventricle of the heart with each heartbeat.

    Measured: 1st Trimester at 8-14 weeks, 2nd Trimester at 22-28 weeks, 3rd Trimester at 34-40 weeks, and 4-12 Weeks Postpartum

  2. Cardiac Output

    The total volume of blood pumped out of the heart and into the rest of the body with each heartbeat.

    Measured: 1st Trimester at 8-14 weeks, 2nd Trimester at 22-28 weeks, 3rd Trimester at 34-40 weeks, and 4-12 Weeks Postpartum

  3. Systemic Vascular Resistance

    The level of force (or resistance) against which the heart must work to pump blood into the circulatory system.

    Measured: 1st Trimester at 8-14 weeks, 2nd Trimester at 22-28 weeks, 3rd Trimester at 34-40 weeks, and 4-12 Weeks Postpartum

  4. Cardiac Index

    A measure of the pumping capacity of the heart, calculated by dividing one's cardiac output by their body surface area.

    Measured: 1st Trimester at 8-14 weeks, 2nd Trimester at 22-28 weeks, 3rd Trimester at 34-40 weeks, and 4-12 Weeks Postpartum

  5. R5

    A respiratory measure of the resistance across all airways, both large and small, using 5Hz soundwaves.

    Measured: 1st Trimester at 8-14 weeks, 2nd Trimester at 22-28 weeks, 3rd Trimester at 34-40 weeks, and 4-12 Weeks Postpartum

  6. R20

    A respiratory measure of the resistance across central/large airways only, using 20Hz soundwaves.

    Measured: 1st Trimester at 8-14 weeks, 2nd Trimester at 22-28 weeks, 3rd Trimester at 34-40 weeks, and 4-12 Weeks Postpartum

  7. X5

    A respiratory measure of the elasticity of airways using 5Hz soundwaves to calculate the difference in energy to and from lung tissue.

    Measured: 1st Trimester at 8-14 weeks, 2nd Trimester at 22-28 weeks, 3rd Trimester at 34-40 weeks, and 4-12 Weeks Postpartum

  8. Fres

    This denotes the Resonant Frequency, which measures the frequency of soundwaves required to balance the internal forces of the lung tissue with its external capacity.

    Measured: 1st Trimester at 8-14 weeks, 2nd Trimester at 22-28 weeks, 3rd Trimester at 34-40 weeks, and 4-12 Weeks Postpartum

  9. AX

    Called the Area of Reactance, this is the measure of the area under the curve from the lowest measured frequency to the Resonant Frequency, and reflects the dysfunction of small airways.

    Measured: 1st Trimester at 8-14 weeks, 2nd Trimester at 22-28 weeks, 3rd Trimester at 34-40 weeks, and 4-12 Weeks Postpartum

  10. R5-R20

    A measure isolating the resistance of small airways, subtracting the R20 value from the R5 value to calculate the difference. Greater levels of this value correspond to greater small airway resistance.

    Measured: 1st Trimester at 8-14 weeks, 2nd Trimester at 22-28 weeks, 3rd Trimester at 34-40 weeks, and 4-12 Weeks Postpartum

Secondary outcomes (7)
  1. Number of Gestational Hypertension

    A state of high blood pressure triggered by the physiological changes specific to pregnancy.

    Measured: 1st Trimester at 8-14 weeks, 2nd Trimester at 22-28 weeks, 3rd Trimester at 34-40 weeks, and 4-12 Weeks Postpartum

  2. Number of Preeclampsia

    A pregnancy-related complication characterized by high blood pressure and systemic organ dysfunction that can be life-threatening.

    Measured: 1st Trimester at 8-14 weeks, 2nd Trimester at 22-28 weeks, 3rd Trimester at 34-40 weeks, and 4-12 Weeks Postpartum

  3. Number of Fetal Growth Restriction

    A complication where the fetus is growing much less than expected for the gestational age of the pregnancy (i.e., estimated fetal weight and/or fetal abdominal circumstance less than the 10th percentile).

    Measured: 1st Trimester at 8-14 weeks, 2nd Trimester at 22-28 weeks, 3rd Trimester at 34-40 weeks, and 4-12 Weeks Postpartum

  4. Number of Spontaneous Preterm Birth

    The spontaneous (labor not induced) delivery of a pregnancy before 37.0 weeks of gestation.

    Measured: 1st Trimester at 8-14 weeks, 2nd Trimester at 22-28 weeks, 3rd Trimester at 34-40 weeks, and 4-12 Weeks Postpartum

  5. Number of Placental Abruption

    A serious complication where the placenta detaches from the inside of the uterus prior to the delivery of the baby.

    Measured: 1st Trimester at 8-14 weeks, 2nd Trimester at 22-28 weeks, 3rd Trimester at 34-40 weeks, and 4-12 Weeks Postpartum

  6. Number of Intensive Care Unit (ICU) Admission

    Admission to the Intensive Care Unit (ICU) wherein a greater level of clinical surveillance and intervention is administered for higher severity cases.

    Measured: 1st Trimester at 8-14 weeks, 2nd Trimester at 22-28 weeks, 3rd Trimester at 34-40 weeks, and 4-12 Weeks Postpartum

  7. Number of Adverse Neonatal Outcomes

    Any adverse health outcomes experienced by the neonate following delivery (i.e., hypoglycemia, tachypnea, respiratory distress, acidemia).

    Measured: 1st Trimester at 8-14 weeks, 2nd Trimester at 22-28 weeks, 3rd Trimester at 34-40 weeks, and 4-12 Weeks Postpartum

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Jul 2026
  2. Study startOct 2026 (estimated)
  3. Primary completionAug 2028 (estimated)
  4. Study completionAug 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07695909
Sponsor's protocol ID
STUDY-26-00575
Acronym
TREMOFLO
Status last verified
Sep 2026
First submitted
2 Jul 2026
Last updated
28 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: All of the individual participant data collected during the trial after deidentification.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in